Researchers use 7 compounds to make stem cells A team of scientists was able to create induced pluripotent stem cells without altering the number of genes or risking mutations. The method uses seven small-molecule chemical compounds including DZNep, an inhibitor that reactivates developmental genes, to reprogram somatic cells to a pluripotent state. The researchers reported in the journal Science that they were able to create fully reprogrammed stem cells, which they called CiPS cells, and produce a conversion rate of 0.2%, which was comparable to conventional techniques for iPS cells. Nature (free content) (7/18) | U.S. researchers ID pathogen-resistant soybean genes Researchers at Purdue University have identified two soybean genes that show strong resistance to Phytophthora sojae, a soilborne pathogen that causes Phytophthora root and stem rot. The discovery could lead to development of disease-resistant soybean cultivars. The team's findings were reported in the journal Theoretical and Applied Genetics. SoutheastFarmPress.com (7/19) | | Industrial & Environmental | Partners sought by DuPont for cellulosic-ethanol venture DuPont is in talks with firms in the U.S., China, Europe, Brazil and Southeast Asia about the possibility of making cellulosic ethanol under a partnership agreement, said Jan Koninckx, the company's global business director for biofuels. "DuPont would take a minority stake and ... we would basically take an active role in setting production up" in the ventures, Koninckx said. Nasdaq.com/Dow Jones Newswires (7/19) | July 2013 BIO Therapeutic Newsletters The BIO Emerging Companies Section Policy Team has compiled the latest news to keep you informed on the action in Washington with respect to the disease category on which your company is focused. Topics covered comprise: Allergy/Infectious Disease/Antiviral; Cardiology/Pulmonology/Blood; Nephrology/Endocrinology/Metabolism/Gastroenterology; Neurology/CNS; Oncology; and Rheumatology/Anesthesia/Inflammation/Pain. BIO has attempted to include updates from biotech stakeholders around Washington, including Congress, FDA, NIH and patient organizations. Access to our July 2013 Therapeutic Newsletters can be found here. Should you have any comments or questions, please contact Charles Crain. |  | Public opinion is a second conscience." -- William Alger, Unitarian minister and writer | | | The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com. | Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
| Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | |
No comments:
Post a Comment